AvantGuard, Inc.

Candida auris isn’t just a looming threat – it’s part of a greater global problem. Fungal infections already afflict over 1 billion people annually, and with climate change enabling fungi to thrive at higher temperatures, the danger continues to escalate. By 2050, drug-resistant pathogens could claim more lives than cancer. Candida auris, with its resistance to drugs, ability to persist on surfaces, and rapid spread in healthcare settings, is a stark warning of what’s to come. At AvantGuard, we’re fighting back with innovation to protect patients, prevent infections, and reduce the rise of antimicrobial resistance. #DrugResistance #CandidaAuris #InfectionPrevention #GlobalHealth #InnovationForGood

Candida auris is on the Centers for Disease Control and Prevention's list of priority pathogens for a reason. With a 40% mortality rate within 30 days of invasive infection, C. auris poses a grave threat. Yet, our current antifungal treatments are increasingly ineffective because of resistance generation, and therefore, the recommendation is not to use antifungal to remove C. auris from the skin and wait to see if an invasive infection develops. At AvantGuard, we’re developing a topical, non-resistance-generating treatment to address this critical gap. Treating cutaneous infections early can prevent invasive infections altogether – saving lives and reducing the burden on healthcare systems. Contact us to learn more. Avantguardinc.com #InnovationForImpact #InfectiousDisease

AvantGuard was originally founded as Halomine in 2018 and emerged from groundbreaking research at Cornell University. Our foundation is built on the power of N-halamines – a natural compound that pairs nitrogen with chlorine to create a potent "microbial death", delivering exceptional antibacterial capabilities. AvantGuard's journey is backed by over 30 years of development with licensed N-halamine technology from both Cornell and Auburn University. Under the leadership of CEO Ted Eveleth, we continue to pioneer innovations that address some of the most pressing global health challenges. Learn more on our website, avantguardinc.com. #AvantGuardInnovation #AntimicrobialTechnology #GlobalHealthSolutions #PioneeringScience

As we step into 2025, we’re excited to reflect on a year of growth and focused innovation at AvantGuard. 2024 was a pivotal year as we expanded our platform technology and honed in on addressing critical health challenges. – Expanding Our Platform Technology: AvantGuard’s versatile technology continues to prove its value across industries. This year, we sharpened our focus on antifungal solutions, particularly in combating Candida auris, a deadly and resistant pathogen. Our efforts in developing novel topical treatments aim to prevent invasive infections and save lives. – Advancing Fundraising Efforts: So far, we’ve raised over $1M in pre-seed funding and are now in the midst of a $5M seed round, with $2.8M in the bank. Combined with $9M in grants from various agencies, these resources are fueling the development of groundbreaking solutions. – Innovating for Global Health: From creating antimicrobial surface coatings to advancing non-resistance-generating treatments, AvantGuard is at the forefront of solving some of the most urgent global health challenges. As we enter 2025, we’re proud of the progress we’ve made and excited about what’s next. Thank you to our supporters and collaborators who are helping us bring these innovations to life. Stay tuned for more milestones ahead and visit our website to learn more! Avantguardinc.com #Innovation #AntifungalSolutions #CandidaAuris #FundraisingSuccess #AvantGuardTechnology

AvantGuard’s cutting-edge polymer technology is unlocking new possibilities in healthcare. Inspired by nature’s pathogen-fighting mechanisms, Avantamine is revolutionizing how fungal infections are treated. Imagine a topical antifungal that not only eliminates fungi but also creates a surface resistant to protein adhesion, providing long-lasting protection. AvantGuard's innovation extends beyond traditional surfaces – from topical antifungals and acne solutions, to wound dressings, and more. Our technology is set to redefine your health including skincare! Discover more about our transformative solutions on our website. avantguardinc.com #AvantGuardInnovation #TopicalAntifungals #SkincareRevolution #FutureOfHealth

Welcome to our antimicrobial resistance (AMR) Special Focus Publication, which features expert insights into the challenges and solutions to tackle the global threat of AMR. Antimicrobial resistance is one of the most pressing global health challenges of our time. It occurs when microorganisms – bacteria, fungi, viruses, and parasites – develop the ability to resist the drugs designed to kill them, rendering treatments ineffective and allowing infections to persist, spread, and become more severe. The consequences of AMR are profound, threatening to reverse decades of medical progress. Without effective antimicrobials, procedures like surgeries, cancer treatments, and organ transplants become perilously risky. This Special Focus Publication offers a comprehensive exploration of antimicrobial resistance, compiling insights from experts, case studies, and innovative strategies to tackle this urgent issue. Sequoia Vaccines Inc QuantaMatrix Vast Therapeutics QSM Diagnostics, Inc AvantGuard, Inc. QURES GROUP LIMITED Quick-Med Technologies #amr #antimicrobialresistance #humanhealth #animalhealth #vaccinedevelopment #health #publichealth

As we look ahead to 2025, AvantGuard's groundbreaking technologies are redefining industries and transforming global health challenges into opportunities for innovation. From revolutionary antimicrobial coatings to versatile molecules like Avantamine, we’re tackling pathogens across surfaces, skin, and beyond – without promoting resistance. Our advancements are helping preserve antibiotics for when they’re truly needed, addressing a $100B problem at its core. With science at the heart of everything we do, AvantGuard is pioneering solutions that safeguard lives and enhance resilience in healthcare, consumer goods, and beyond. Stay tuned as we continue leading the charge into a safer, healthier future. #InnovatingHealth #AvantGuard2025 #AntimicrobialSolutions #GlobalHealth

This holiday season, we celebrate the joy, teamwork, and connections that define AvantGuard. To our incredible team, partners, and investors – thank you for being part of our journey. Here’s to shared successes and exciting possibilities ahead. Wishing you a joyful holiday season and a bright New Year! #HappyHolidays #SeasonsGreetings #AvantGuard

Protection is everywhere with AvantGuard. Whether you’re at home, traveling, working, or in a healthcare setting, our innovative technology can offer protection to every surface you touch. AvantGuard’s versatile solutions can be soluble, adhere to surfaces, or even be integrated into materials, redefining safety and cleanliness. Imagine a world where protection travels with you. With AvantGuard, the future of surface protection is coming – delivering innovation that keeps you safe no matter where you are. 🌍✨ #EverywhereProtection #FutureOfChlorine #AntimicrobialInnovation #SafeEverywhere #AvantGuard

What is Candida auris, and why is it a growing global threat? Candida auris (C. auris) is not your typical fungus. It’s a drug-resistant yeast that thrives where most fungi can't—at human body temperature and in saline conditions. This makes it uniquely dangerous, particularly in healthcare settings, where it causes large, hard-to-control outbreaks. Here’s why C. auris is so alarming: ➡️ High Infection Risk: It rapidly colonizes the skin of immunocompromised patients, with a 20% chance of infection. Among those infected, the mortality rate exceeds 30% within 30 days. ➡️ Environmental Persistence: C. auris can shed into the environment, surviving for long periods on surfaces and resisting standard disinfectants. Just 4 hours of contact can be enough to colonize a patient or contaminate a surface. ➡️ Limited Treatment Options: There is no proven protocol to de-colonize C. auris on patients. Even daily bathing with 2% chlorhexidine gluconate (CHG), the standard of care, has shown little success. With infection rates in the U.S. rising by 70% annually and colonization rates in some healthcare facilities exceeding 70%, C. auris has become the first fungal pathogen labeled an urgent threat by the Centers for Disease Control and Prevention and a critical priority by the World Health Organization. At AvantGuard, we’re committed to tackling this threat with a three-pronged approach. Learn more about how we’re fighting C. auris and protecting you here: https://lnkd.in/gADuXggA #CandidaAuris #HealthcareInnovation #InfectionControl #GlobalHealthThreat #AvantGuard